Incyte‘s patent involves compounds that target adenosine receptors to treat diseases like cancer, inflammation, cardiovascular, and neurodegenerative conditions. Claim 1 specifically covers the treatment of various cancers by administering a specific compound. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11884665B2) discloses a method for treating various types of cancer in patients by administering a specific compound. The method involves administering a therapeutically effective amount of 3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof. The patent claims cover the treatment of diseases such as bladder cancer, lung cancer (including non-small cell lung cancer), breast cancer, ovarian cancer, colorectal cancer, prostate cancer (including metastatic castration-resistant prostate cancer), head and neck cancer (specifically head and neck squamous cell carcinoma).
Among the specific claims outlined in the patent, the method particularly focuses on the treatment of head and neck cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, and pancreatic cancer. By administering the specified compound or its salt, the patent aims to provide a therapeutic approach for these diseases. The patent's claims highlight the potential application of this method in targeting various types of cancer, showcasing a promising avenue for the development of treatments in the field of oncology. The specificity of the compound and the range of cancers it targets demonstrate the potential impact of this method on improving patient outcomes and advancing cancer treatment strategies.
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
